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Abstract
Background. Systemic inflammation has been linked with mood disorder and cognitive
impairment. The extent of this relationship remains uncertain, with the effects of serum
inflammatory biomarkers compared to genetic predisposition toward inflammation yet to be
clearly established.
Methods. We investigated the magnitude of associations between C-reactive protein (CRP)
measures, lifetime history of bipolar disorder or major depression, and cognitive function
(reaction time and visuospatial memory) in 84,268UKBiobank participants. CRPwasmeasured
in serum and a polygenic risk score for CRP was calculated, based on a published genome-wide
association study. Multiple regression models adjusted for sociodemographic and clinical
confounders.
Results. Increased serum CRP was significantly associated with mood disorder history (Kruskal–
Wallis H =196.06, p <0.001, η2 =0.002) but increased polygenic risk for CRP was not (F =0.668,
p =0.648, η2 <0.001). Compared to the lowest quintile, the highest serum CRP quintile was
significantly associated with both negative and positive differences in cognitive performance (fully
adjusted models: reaction time B =0.030, 95% CI=0.052, 0.008; visuospatial memory B =
0.066, 95% CI=0.042, 0.089). More severe mood disorder categories were significantly associated
with worse cognitive performance and this was not moderated by serum or genetic CRP level.
Conclusions. In this large cohort study, we found that measured inflammation was associated
withmood disorder history, but genetic predisposition to inflammationwas not. The association
between mood disorder and worse cognitive performance was very small and did not vary by
CRP level. The inconsistent relationship between CRP measures and cognitive performance
warrants further study.
Introduction
Inflammation has for several years been linked with the development of mood disorder and
cognitive impairment [1-3]. However, uncertainty remains regarding the extent of this relation-
ship and the effects of serum inflammation levels compared to genetic predisposition toward
inflammation.
C-reactive protein (CRP) is an inflammatory protein produced primarily by the liver as part of
the acute phase response, which is initiated in response to changes in homeostasis due to insults
such as infection or tissue injury. CRP levels rise exponentially as part of the acute phase response
thus CRP is a useful biomarker for inflammation within the body. Once the responsible insult has
been resolved, CRP levels rapidly decrease due to the protein having a short half-life in the blood.
However, in chronic conditions, CRP levels can remain elevated to a lesser degree [4,5].
Elevated levels of CRP have been observed in people with bipolar disorder and have been
associated with an increased risk of depression [6-8]. Increased CRP levels have also been shown
to be associated with more severe symptoms of depression [9,10]. An association between
increased CRP levels and worse cognitive function has been reported [11].
Evidence exists of a relationship between cognitive function and mood disorder with
increased rates of cognitive impairment observed in those with depressive symptoms compared
to those without [12,13]. Those with major depressive disorder and bipolar disorder have
evidence of cognitive impairment during both euthymia and illness episodes compared to healthy
individuals, suggesting an overlap between the mechanisms involved in mood disorders and
cognitive impairment [14].
Inflammation may contribute to both mood disorder and cognitive impairment via several
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to the development of metabolic disease, resulting in even greater
levels of inflammation within the body culminating in further
disease development [1]. Similarly, patients with a history of
repeated low-grade infections (evidence of a high inflammatory
profile) are more likely to develop mood disorder in later life
[15]. Other proposed mechanisms include dysregulation of the
hypothalamic–pituitary–adrenal axis; cytokine-mediated neuronal
destruction; altered concentrations of monoamine neurotransmit-
ters; and decreased gray matter density in the brain [1,16-18].
Genome wide association studies (GWAS) have been used to
investigate the specific common genetic variants associated with
diseases or traits (single nucleotide polymorphisms; SNPs). Once
SNPs associated with a trait are identified it is then possible to
calculate a polygenic risk score (PRS), which represents an indi-
vidual’s genetic predisposition for that trait based on the number of
risk alleles they possess at those SNPs for the trait in question. PRS
have been used to find evidence of genetic overlap between traits,
including between inflammatory biomarkers and disease [19,20].
Although useful as a measure of an individual’s current inflam-
matory state, serum CRP levels can be influenced by confounding
factors such as recent disease. PRSs have been used as a more stable
reflection of lifetime potential for higher CRP. The use of a poly-
genic risk score for C-reactive protein level (PRS-CRP) within a
study would enable assessment of an individual’s genetic predispo-
sition toward inflammation excluding recent factors [21]. Including
both serumCRP and PRS-CRPwithin the same studywould ensure
the effects of current and genetic levels of CRP were accounted for
when investigating the relationship between CRP, mood disorder,
and cognitive function.
To our knowledge, no study has investigated the association
between serum CRP level, PRS-CRP, mood disorder, and cognitive
function. This study may help to improve our understanding of the
causes and consequences of mood disorder.
Aims
The aim of this study of UK Biobank participants was to determine
the magnitude of the associations between CRP, mood disorder,
and cognitive function. In the first instance, the study aimed to
assess whether serum CRP levels or PRS-CRP were increased in
participants with a lifetime history of bipolar disorder, recurrent
major depression, or a single episode of major depression. The
study also aimed to investigate whether serum CRP levels were
associated with PRS-CRP. Finally, the study aimed to determine
whether an increased serum CRP level or PRS-CRP moderated the




This research has been conducted using the UK Biobank Resource
under Application Number 11332 (PI: Cullen). Participants of the
study were adults aged 40–70 who participated in the UK Biobank
study between 2006 and 2010 and completed a baseline assessment at
one of 22 assessment centers across the UK. The assessment process
included a touchscreen questionnaire, a face-to-face interview with a
research nurse, and measurement-taking during which participants
were asked to give a blood sample. In the final 2 years of the
recruitment period, a touchscreen questionnaire regarding mood
disorder was added to the assessment process. Over 500,000
participants were recruited during this baseline phase of which
172,751 completed a touchscreen questionnaire regarding mood
disorder [22,23]. The UK Biobank has approval from the NHS
National Research Ethics Service as a research tissue bank
(References 16/NW/0274 and 11/NW/0382).
Participants were excluded from the present study if they did not
complete the mood disorder questionnaire; did not provide enough
information to derive a mood disorder classification; or did not
have data for serum CRP level or SNPs associated with CRP level.
Participants were also excluded if they were not of white British
ancestry; this was necessary because spurious associations arising
from population stratification may occur if the study sample
includes groups of individuals who differ systematically in both
genetic ancestry and the phenotype of interest [24]. Also excluded
were those who failed genotyping quality control and those who
were closely related (third degree or closer) to othermembers of the
cohort.
History of mood disorder
Participants answered touchscreen questions relating to lifetime
incidence of depressive and manic symptoms, and current mood
state. A shortened and adapted version of the Patient Health
Questionnaire formed the basis of questions asked on current
depressive symptoms whilst the Structured Clinical Interview for
DSM-IV Axis I Disorders was used to formulate questions on
lifetime depressive and manic symptoms [25,26]. UK Biobank
did not administer a measure of current manic symptom severity,
due to time restrictions in the overall visit duration.
Participants were classified into different mood disorder groups
based on their responses to the mood disorder questionnaire. The
mood disorder groups were defined using criteria previously
described by Smith et al. [27]. These criteria were based on self-
reported lifetime experiences of features of BD or major depression.
The groups included in the studywere bipolar disorder type I (BD-I),
bipolar disorder type II (BD-II), probable recurrentmajor depression
(severe), probable recurrent major depression (moderate), and a
single probable episode ofmajor depression. A hierarchical structure
was used during allocation of participants to one of the mood
disorder groups. This hierarchy followed the order listed previously
with BD-I deemed the most severe mood disorder and a single
probable episode of major depression deemed the least severe. Par-
ticipants who met the criteria for multiple groups were allocated to
the most severe mood disorder for which they met the criteria.
Participants who failed tomeet the required criteria for classification
into one of the defined mood disorder groups were included in a
separate group defined as no mood disorder. This group acted as a
control for the study. All groups were mutually exclusive. No struc-
tured questionnaires were administered by UK Biobank at this visit
for other psychiatric conditions and it is possible that participants in
any of the groups (including controls) had a history of other condi-
tions apart from mood disorder.
Cognitive function
To assess cognitive function participants were asked to complete
several tasks on a touchscreen. These novel tasks were designed
specifically for UK Biobank and completed by participants without
supervision. Two tasks were administered throughout the baseline
recruitment period and were analyzed in this study—reaction time
and pairs matching (test of visuospatial memory). Both tasks have
been shown to have moderate correlations with other standard
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cognitive tests in the same domains (r =0.33–0.52), and both show
moderate test–retest correlations over 4weeks (r =0.41–0.55) [28].
Reaction time
The participant was shown a pair of cards together on the touchsc-
reen and asked to press a button if the cards shown were identical.
In total, 12 pairs of cards were shown. Results were based on the
mean time taken to press the button in milliseconds [29].
Pairs matching
The participant was shownmultiple pairs of cards at once and asked
to memorize the location of as many matching pairs as possible.
The cards were turned face down and the participant was asked to
touch as many pairs as possible in as few attempts as possible. Two
rounds of matching were performed—first with three pairs of cards
and then with six pairs of cards. Only the six-pair version was used
in this study, to provide a sufficient range of data for analysis.
Results were based on the number of errors made by the participant
[30].
Serum CRP level
Serum CRP level (mg/L) was measured by immunoturbidimetric
high-sensitivity analysis on a BeckmanCoulter AU5800 [31-33]. As
this was not normally distributed, we report the median and
quartiles below. Participants were also categorized into quintiles
based on their serum CRP level with one representing the lowest
serum CRP levels and five representing the highest serum CRP
levels, to facilitate analysis of statistical interactions.
PRS for CRP level
Genotyping, imputation, and quality control were done centrally by
UK Biobank [34]. A PRS-CRP was calculated for each study par-
ticipant based on 52 SNPs identified by Ligthart et al. in a GWAS
meta-analysis as being significantly associated with serum CRP
levels [35]. The PRS-CRP used in the study was created using
47 of these SNPs as data were not available, or did not have
sufficient imputation quality, for the remaining five in the UK
Biobank database. The score was an unweighted sum of the number
of risk alleles each participant possessed across these 47 SNPs
(missing SNPs for a given participant were coded as 0 unless all
SNPs were missing, in which case the participant was excluded
from analysis). To investigate whether this score should have been
adjusted for genetic ancestry, the first 20 genetic principal compo-
nents were included in a regression model. As this did not affect the
results, the raw PRS-CRP score was used in the analyses reported in
this study. However, batch was included as a covariate in multivar-
iable regression models involving the PRS-CRP, to account for any
confounding effects of the genotyping process.
Covariates and background characteristics
Baseline sociodemographic, lifestyle, and clinical characteristics for
each participant were obtained using the UK Biobank database.
Potential covariates within the analyses were defined as age, sex,
Townsend deprivation score (categorized into quintiles with one
representing the least deprived and five representing the most
deprived), educational status (dichotomized according to whether
or not participants held a university/college degree), and current
depressive symptoms (score ranging from zero to 12). Information
on other background characteristics was also obtained consisting of
smoking (“Never,” “Former,” “Current”), frequency of alcohol
intake (“Daily or almost daily,” “3–4 times per week,” “1–2 times
per week,” “1–3 times per month,” “Special occasions only,”
“Never,”) bodymass index (BMI; kg/m2), and current psychotropic
medication use (list of medications reported by us previously) [36].
Statistical analysis
The data were initially summarized using descriptive statistics. A
Kruskal–Wallis H test assessed for differences in serum CRP level by
mood disorder group, and a one-way analysis of variance (ANOVA)
tested for group differences in PRS-CRP (as this was normally
distributed). The relationship between serum CRP level and PRS-
CRP was assessed with Spearman’s rank correlation coefficient. To
enable comparison of the cognitive tests, the raw scores for each test
were standardized to z-scores (mean=0, standard deviation=1)
within 5-year age bands, with higher scores representing better
performance. Two sets of multiple linear regression models were
constructed to investigate associations between each measure of
cognitive function (dependent variable), and mood disorder group
and CRP (independent variables). One set of regression models
included serum CRP level whilst the other included PRS-CRP. Each
model accounted for confounders and tested for interactions
between mood disorder group and the CRP variable included.
Statistical significance in the study was defined as p < 0.05.
Correction for multiple comparisons was done where appropriate,
for example, Bonferroni post-hoc pairwise comparisons following
Kruskal–Wallis test. All analyses were conducted using IBM SPSS
Statistics 26 except conversion of Kruskal–Wallis and ANOVA test
statistics to effect size η2, which was done using the calculators
provided at https://www.psychometrica.de/effect_size.html and
https://osf.io/wgsi3/, respectively.
Results
Characteristics of the sample
Of the 502,543 participants in the UK Biobank cohort, 84,268 were
included in the study after the exclusion criteria had been applied
(Figure 1).
Of the 84,268 study participants, 502 (0.6%) were classified into
the BD-I group, 467 (0.6%) into the BD-II group, 5963 (7.1%) into
the recurrent major depression (severe) group, 10,739 (12.7%) into
the recurrent major depression (moderate) group, and 5739 (6.8%)
into the single episode of major depression group. The remaining
60,858 (72.2%) were classified into the no mood disorder control
group. The demographic and clinical characteristics of the partic-
ipants are shown in Table 1. There was an over-representation of
women in the depression groups, and of individuals in the most
deprived Townsend deprivation score quintile in the BD-I group.
The mean current depressive symptoms score was lowest in the
control group with the highest witnessed in the BD-I group.
Relationship between serum CRP level and mood disorder
The null hypothesis that serum CRP level was the same across all
mood disorder groups was rejected (Kruskal–Wallis H statistic =
169.06, df = 5, p < 0.001, η2 =0.002). Post-hoc pairwise tests of
differences in serum CRP level across the mood disorder groups
are displayed in Table 2. A significant difference was observed
between the no mood disorder group and the other mood disorder
groups apart from the BD-II group (p =0.480).
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Relationship between PRS for CRP level and mood disorder
One-way ANOVA indicated no significant difference between the
mood disorder groups in terms of PRS-CRP (F(5, 84262) = 0.668,
p = 0.648, η2 =0.002).
Relationship between serum CRP level and PRS for CRP level
The Spearman’s rank correlation coefficient was 0.167 (p < 0.001)
showing significant evidence of a small positive correlation between
serum CRP level and PRS-CRP.
Relationship between cognitive function, mood disorder, and
serum CRP level
Separate regression models were conducted for the dependent
variables of reaction time (Table 3) and pairs matching (Table 4),
with the same independent variables and covariates.
The unadjusted model for reaction time z-score showed serum
CRP level quintiles four and five, BD-I, recurrent major depression
(severe), and recurrent major depression (moderate) were signifi-
cantly associated with lower cognitive performance. In the adjusted
model for reaction time, only serum CRP level quintile five and
recurrent major depression (severe) remained significantly associ-
ated with lower cognitive performance. As mood disorder severity
increased larger decreases in performance were observed—with the
exception that recurrent major depression (severe) showed a larger
decrease in performance compared to BD-II.Most of the effect sizes
decreased with adjustment for confounders.
The unadjusted pairs matching model showed serum CRP
quintile three, four, and five, and a single episode of major depres-
sion were significantly associated with higher cognitive perfor-
mance whilst BD-I, recurrent major depression (severe), and
recurrent major depression (moderate) were significantly associ-
ated with lower cognitive performance. In the adjusted model all
serum CRP quintiles were significantly associated with a higher
pairs matching z-score whilst BD-I, recurrent major depression
(severe), and recurrent major depression (moderate) all remained
significantly associated with a lower pairs matching z-score. The
favorable effect sizes increased in line with increasing serum CRP
level quintiles. Compared to the unadjusted model, the effect sizes
increased for all serum CRP quintiles whilst they decreased for all
mood disorder groups.
Relationship between cognitive function, mood disorder, and
PRS for CRP level
The results of these models are shown in Table 5. The unadjusted
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Figure 1. Flowchart showing the participants included in the study. CRP, C-reactive protein; SNP, single nucleotide polymorphism.
4 David C. Milton et al.





















Age mean (SD), years 55 (8) 56 (8) 56 (8) 56 (8) 57 (8) 58 (8)
Gender female n (%) 233 (46.4) 208 (44.5) 3422 (57.4) 7321 (68.2) 3585 (62.5) 29657 (48.7)
Townsend score quintile
Missing data n 0 1 11 25 11 78
1 (least deprived) n (%) 53 (10.6) 64 (13.7) 861 (14.5) 1861 (17.4) 1062 (18.5) 11803 (19.4)
2 66 (13.1) 85 (18.2) 1064 (17.9) 2213 (20.7) 1207 (21.1) 13771 (22.7)
3 100 (19.9) 80 (17.2) 1189 (20.0) 2263 (21.1) 1222 (21.3) 13400 (22.0)
4 130 (25.9) 120 (25.8) 1353 (22.7) 2377 (22.2) 1306 (22.8) 12586 (20.7)
5 153 (30.5) 117 (25.1) 1485 (24.9) 2000 (18.7) 931 (16.3) 9220 (15.2)
Educated to degree level
Missing data n 2 1 29 46 22 452
Yes n (%) 171 (34.2) 169 (36.3) 2099 (35.4) 3608 (33.7) 2068 (36.2) 19377 (32.1)
Smoking status
Missing data n 3 1 12 18 13 196
Current n (%) 102 (20.4) 94 (20.2) 937 (15.7) 1181 (11.0) 570 (10.0) 4790 (7.9)
Former 186 (37.3) 178 (38.2) 2264 (38.0) 3971 (37.0) 2128 (37.2) 21262 (35.0)
Never 211 (42.3) 194 (41.6) 2750 (46.2) 5569 (51.9) 3028 (52.9) 34610 (57.1)
Alcohol frequency
Missing data n 1 0 3 2 4 17
Daily or almostdailyn (%) 109 (21.8) 115 (24.6) 1240 (20.8) 2173 (20.2) 1180 (20.6) 13821 (22.7)
3–4 times per week 90 (25.2) 83 (17.8) 1182 (19.8)) 2381 (22.2) 1398 (24.4) 15309 (25.2)
1–2 times per week 103 (20.6) 119 (25.5) 1322 (22.2) 2738 (25.5) 1480 (25.8) 16002 (26.3)
1–3 times per month 53 (10.6) 61 (13.1) 740 (12.4) 1415 (13.2) 700 (12.2) 6232 (10.2)
Special occasions only 76 (15.2) 38 (8.1) 812 (13.6) 1309 (12.2) 626 (10.9) 5939 (9.8)
Never 70 (14.0) 51 (10.9) 664 (11.1) 721 (6.7) 351 (6.1) 3538 (5.8)
Body mass index (kg/m2)
Missing data n 3 2 36 47 23 225
Mean (SD) 28.4 (5.2) 27.9 (4.9) 28.0 (5.2) 27.8 (5.1) 27.5 (4.9) 27.2 (4.5)
On psychotropic
medication
Missing data n 9 7 70 156 95 765
Yes n (%) 258 (52.3) 65 (14.1) 2071 (35.1) 2023 (19.1) 470 (8.3) 2175 (3.6)
Current depressive symptoms score (0–12)
Missing data n 30 38 418 753 385 4585
Mean (SD) 4 (3) 3 (3) 3 (3) 2 (2) 1 (2) 1 (1)
Serum CRP level (mg/L)
Median (25th–75th
percentile)
1.50 (0.73–3.43) 1.45 (0.68–3.02) 1.47 (0.71–3.03) 1.40 (0.68–2.90) 1.35 (0.68–2.73) 1.25 (0.63–
2.56)
Serum CRP level quintile
Missing data n 0 0 0 0 0 0
1 (lowest) n (%) 98 (19.5) 88 (18.8) 1098 (18.4) 2039 (19.0) 1102 (19.2) 12763 (21.0)
2 90 (17.9) 89 (19.1) 1109 (18.6) 2145 (20.0) 1193 (20.8) 13080 (21.5)
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either reaction time z-score or pairs matching z-score. There were
significant differences by mood disorder group, however: BD-I was
associated with worse performance on both cognitive tests, and a
single episode of major depression was associated with a higher
pairs matching z-score. After adjusting for confounders, PRS-CRP
remained unassociated with reaction time z-score but became
significantly associated with a higher pairs matching z-score.
The adjustment for confounders resulted in a decrease in the
magnitude of cognitive differences associated with mood disorder
in almost every group, with some results no longer significant.
Recurrent major depression (severe) was significantly associated
with a lower reaction time z-score and pairsmatching z-scorewhilst
BD-I and recurrent major depression (moderate) were significantly
associated with a lower pairs matching z-score only. The adjusted
effect sizes across mood disorder groups were generally larger for
pairs matching compared to reaction time, although all effect sizes
were very small in absolute terms.
Interactions between CRP level and mood disorder
Tests for interactions between serumCRP level andmood disorder,
and PRS-CRP and mood disorder, were conducted in the adjusted
models for each cognitive test. One significant interaction was
observed in one of the pairs matching models (between serum
CRP level quintile three and recurrent major depression (severe)),
but in the context of otherwise non-significant interaction coeffi-
cients this was thought to be a spurious finding and so stratified
models were not conducted.
Discussion
In this large cohort of individuals of white British ancestry in middle
to early old age, some evidence was found of associations between
CRP, mood disorder, and cognitive function. Our results suggested
that increased serum CRP level was significantly associated with a
history of mood disorder whereas an increased PRS-CRP was not.
However, a significant (albeit small) positive correlationwas observed
between serumCRP level andPRS-CRP.We found, after adjusting for
confounders, that the highest serum CRP levels were significantly
associated with worse performance on a reaction time test. Con-
versely, and unexpectedly, higher serum and PRS-CRP levels were
significantly associated with better performance on the pairs match-
ing visuospatial memory test. Importantly, these findings may not be
of clinical significance as the coefficients for the differences in cogni-
tive performance observed—whether higher or lower—were very
small.
The observed association between mood disorder and worse cog-
nitive function is in line with previous research [12-14]. Significantly
lower reaction time performance was observed in the recurrent major
depression (severe) group, whilst BD-I, recurrent major depression
(severe), and recurrentmajor depression (moderate)were significantly
associatedwith lower pairsmatching performance (thiswas borderline
in the case of recurrent major depression (moderate)). As mood
disorder increased in severity, the negative association with cognitive
function tended to increase in magnitude, with BD-I associated with
the largest difference in cognitive function. Again the coefficients for
these differences were very small so these associations may not be
clinically significant although further research may be warranted to
determine this. The overall absence of significant interactions between
CRP measures and the mood disorder groups suggests that the
relationship between mood disorder history and cognitive function
did not vary substantially across different levels of CRP.
It was reasonable to hypothesize that increased levels of inflam-
mation would be associated with mood disorder history and a
reduction in cognitive performance as shown by previous studies
[6,7,11]. As such, the mixed results in our study are surprising. The
lack of significant association between PRS-CRP and mood disor-
der was perhaps unexpected although the positive correlation
between serum CRP level and PRS-CRP shows there may be more
to investigate regarding this relationship. It is unclear why
increased CRP levels were associated with both positive and neg-
ative effects on cognitive performance.
This study is one of the first to explore the association between
CRP and mood disorder incorporating both serum CRP level and
PRS-CRP. Many studies have investigated the association between
serum CRP level and psychiatric disorder, but few have also
included PRS-CRP [8,37,38]. One previous study investigated the
relationship between PRS-CRP and various psychiatric and somatic
disorders but used a PRS comprising of only 18 SNPs from an older
GWAS [39]. We have extended this area of research by comparing
serum CRP levels, using a PRS-CRP including 47 SNPs, and inves-






















3 93 (18.5) 93 (19.9) 1180 (19.8) 2068 (19.3) 1148 (20.0) 12203 (20.1)
4 92 (18.3) 101 (21.6) 1249 (20.9) 2203 (20.5) 1141 (19.9) 11904 (19.6)
5 129 (25.7) 96 (20.6) 1327 (22.3) 2284 (21.3) 1155 (20.1) 10908 (17.9)
PRS for CRP level (0–94)
Mean (SD) 54 (4) 54 (4) 55 (5) 54 (4) 54 (4) 54 (4)
Reaction time (ms)
z-scorea mean (SD) 0.09 (1.00) 0.02 (0.96) 0.08 (0.99) 0.03 (0.96) 0.02 (0.96) 0.02 (0.97)
Pairs matching (errors)
z-scorea mean (SD) 0.13 (1.05) 0.24 (1.00) 0.21 (1.06) 0.28 (1.03) 0.34 (1.02) 0.31 (1.03)
Abbreviations: CRP, C-reactive protein; mg/L, milligrams per liter; ms, milliseconds; PRS, polygenic risk score; SD, standard deviation.
aHigher z-score indicates better performance.
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The inclusion of serum and genetic CRP variables within the
same study allowed us to compare the effect of current measured
inflammation levels, versus genetic predisposition to inflammation,
on mood disorder history and cognitive performance. The use of a
47 SNP PRS-CRP represents an advance on previous research, but
there is scope for a future study to use the full GWAS results from
the Ligthartmeta-analysis to construct a weighted PRS across all the
CRP-associated SNPs identified, rather than just the genome-wide
significant SNPs used in this study [35].
Limitations
The UK Biobank cohort is not representative of the UK population.
Participants are more likely to live in less socio-economically
deprived areas, be more highly educated and report fewer health
conditions than the general population [40]. We also restricted our
analyses to white British participants. The results of this study are
therefore not generalizable to the UK population. In particular, the
time and effort required to opt into participate and attend a detailed
assessment visit may have meant that people with worse cognitive
function and/or more severe affective symptoms are under-
represented in the UK Biobank cohort. It is also likely that the
UK Biobank cohort is less socio-economically deprived and more
healthy than clinical samples used in some previous studies of CRP
and mental health. The restricted age range of the cohort may be a
further limitation and it will be informative to investigate age-
related differences in the associations of interest as the cohort is
followed up longitudinally.
This study did not investigate the relationship between cardio-
metabolic health and CRP levels. Increased BMI has been shown to
be associated with higher serum CRP levels whilst increased CRP
levels have been found to be associated with medical conditions
such as hypertension and type 2 diabetes [41,42]. Accounting for
BMI and conditions associated with increased CRP levels may
Table 2. Post-hoc pairwise tests of differences in serum CRP quintiles across mood disorder groups.
Mood disorder category Mood disorder category Test statistic Adjusted p-Value
No mood disorder Bipolar disorder type I 3.257 0.017
Bipolar disorder type II 2.144 0.480
Recurrent major depression (severe) 9.428 <0.001
Recurrent major depression (moderate) 8.879 <0.001
Single episode major depression 4.608 <0.001
Bipolar disorder type I No mood disorder 3.257 0.017
Bipolar disorder type II 0.721 1.000
Recurrent major depression (severe) 0.388 1.000
Recurrent major depression (moderate) 1.161 1.000
Single episode major depression 1.769 1.000
Bipolar disorder type II No mood disorder 2.144 0.480
Bipolar disorder type I 0.721 1.000
Recurrent major depression (severe) 0.589 1.000
Recurrent major depression (moderate) 0.141 1.000
Single episode major depression 0.748 1.000
Recurrent major depression (severe) No mood disorder 9.428 <0.001
Bipolar disorder type I 0.388 1.000
Bipolar disorder type II 0.589 1.000
Recurrent major depression (moderate) 2.167 0.454
Single episode major depression 3.477 0.008
Recurrent major depression (moderate) No mood disorder 8.879 <0.001
Bipolar disorder type I 1.161 1.000
Bipolar disorder type II 0.141 1.000
Recurrent major depression (severe) 2.167 0.454
Single episode major depression 1.792 1.000
Single episode major depression No mood disorder 4.608 <0.001
Bipolar disorder type I 1.769 1.000
Bipolar disorder type II 0.748 1.000
Recurrent major depression (severe) 3.477 0.008
Recurrent major depression (moderate) 1.792 1.000
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improve our understanding of the results obtained from this study.
Future research should approach these questions using amediation
or structural equation modeling framework to map out the
assumed pathways between mood disorder, inflammation, and
cognitive function, to understand the potential mediating role of
cardiometabolic disease and associated risk factors including smok-
ing, alcohol, and obesity.
Another limitation of the study was that CRP was the only
inflammatory biomarker studied. Many inflammatory biomarkers
such as interleukin-1 and tumor necrosis factor alpha are thought
to be associated with mood disorder and cognitive impairment
[43,44]. Investigating these other biomarkers may better explain
the association between inflammation, mood disorder, and
cognitive function, as they reflect more specific inflammatory
pathways rather than the general inflammatory levels which are
indicated by CRP. Lastly, we note that only two cognitive tests were
analyzed in this study; future studies should make use of additional
cognitive measures administered at follow-up waves, to investigate
potential group differences in other cognitive domains such as
verbal memory and executive function.
Conclusion
Our findings extend the work previously done in this area and
indicate that current measured inflammation levels appear to be of
greater relevance than lifetime genetic tendency toward
Table 3. Multiple regression results for the relationship between reaction time z-score, mood disorder group and serum CRP level quintile before and after adjusting
for confounders.
Unadjusted model Fully adjusted modela
Coefficient (95% CI) p-Value Coefficient (95% CI) p-Value
Reaction time z-scoreb
Serum CRP level quintile
2 0.002 (0.018 to 0.023) 0.830 0.007 (0.014 to 0.028) 0.512
3 0.019 (0.040 to 0.001) 0.067 0.001 (0.021 to 0.022) 0.963
4 0.030 (0.051 to 0.009) 0.004 0.004 (0.017 to 0.026) 0.696
5 0.089 (0.110 to 0.068) <0.001 0.030 (0.052 to 0.008) 0.007
Bipolar disorder type I 0.111 (0.196 to 0.025) 0.011 0.064 (0.152 to 0.024) 0.156
Bipolar disorder type II 0.042 (0.130 to 0.046) 0.354 0.032 (0.123 to 0.060) 0.495
Recurrent major depression (severe) 0.100 (0.126 to 0.074) <0.001 0.058 (0.085 to 0.030) <0.001
Recurrent major depression (moderate) 0.049 (0.069 to 0.029) <0.001 0.002 (0.024 to 0.019) 0.829
Single episode major depression 0.003 (0.029 to 0.023) 0.809 0.016 (0.011 to 0.043) 0.236
Abbreviations: CI, confidence interval; CRP, C-reactive protein.
aFull model adjusted for age, gender, Townsend deprivation score, educational status, current depressive symptoms.
bLinear regression; omitted reference group was the mood disorder control group and serum CRP quintile 1; coefficients are in z-score units (higher = better performance).
Table 4. Multiple regression results for the relationship between pairs matching z-score, mood disorder group and serum CRP level quintile before and after
adjusting for confounders.
Unadjusted model Fully adjusted modela
Coefficient (95% CI) p-Value Coefficient (95% CI) p-Value
Pairs matching z-scoreb
Serum CRP level quintile
2 0.021 (0.000 to 0.043) 0.055 0.032 (0.010 to 0.055) 0.005
3 0.030 (0.008 to 0.052) 0.008 0.054 (0.031 to 0.077) <0.001
4 0.029 (0.007 to 0.051) 0.010 0.060 (0.037 to 0.083) <0.001
5 0.027 (0.005 to 0.049) 0.019 0.066 (0.042 to 0.089) <0.001
Bipolar disorder type I 0.180 (0.272 to 0.088) <0.001 0.163 (0.258 to 0.067) 0.001
Bipolar disorder type II 0.074 (0.169 to 0.022) 0.130 0.065 (0.164 to 0.034) 0.200
Recurrent major depression (severe) 0.104 (0.131 to 0.076) <0.001 0.095 (0.125 to 0.065) <0.001
Recurrent major depression (moderate) 0.029 (0.050 to 0.007) 0.009 0.025 (0.048 to 0.002) 0.036
Single episode major depression 0.032 (0.004 to 0.060) 0.026 0.027 (0.002 to 0.056) 0.070
Abbreviations: CI, confidence interval; CRP, C-reactive protein.
aFull model adjusted for age, gender, Townsend deprivation score, educational status, current depressive symptoms.
bLinear regression; omitted reference group was the mood disorder control group and serum CRP quintile 1; coefficients are in z-score units (higher = better performance).
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inflammation, with regard to mood disorder history. It may be that
inflammatory events during life have a larger bearing on the
development of mood disorder compared to genetic predisposition
toward increased levels of inflammation. However, there was a
significant positive correlation between serum CRP level and
genetic predisposition to higher CRP, which may mean that a
relationship does exist between PRS-CRP and mood disorder but
could not be detected with the available data in this study. The
association between mood disorder and lower cognitive perfor-
mance was small and did not appear to be moderated by CRP level.
The finding that CRP measures were significantly associated with
both positive and negative differences in cognitive performance
requires further investigation.
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